Savara Expands Board of Directors, Appoints Three New Members
Posted on: Wednesday, 4 March 2009, 07:00 CST
Nevan Elam, Former Head of Nektar Therapeutic's Pulmonary Business Unit, Among New Board of Directors Members
"We are honored to have these new members join the Board of Directors," said
"Savara's formulation technology combines the features of nanoparticles in structured microparticles to yield a powder with ideal aerodynamic properties for inhalation. Their approach is unique and addresses many of the challenges associated with existing formulation technologies. I am excited to be a part this company and to help guide the next generation pulmonary drug delivery technology," said Mr. Elam.
Mr. Elam, 41, is a former member of the executive management team of Nektar Therapeutics where he served as senior vice president, head of the pulmonary business unit. In this role, he oversaw all pulmonary business including research and development, manufacturing and strategic partnerships. Most recently Mr. Elam was responsible for the sale of Nektar's pulmonary business to Novartis for
Dr. Bilby, 49, is president & CEO of Terapio, a pharmaceutical company developing a pipeline of protein-based therapeutics. He is a four-time biotechnology CEO with more than 20 years of entrepreneurial leadership and executive management experience - both domestically and in
Mr. Dennis, 41, is currently senior director of International Equities, Invesco AIM. As a global equity strategist, he has extensive experience analyzing business models, corporate strategies and market trends with a particular emphasis on the European pharmaceutical industry. He is involved in several different funds and mandates with a collective net asset value of approximately
About Savara, Inc.
Savara (www.savarapharma.com) is developing next generation pulmonary drug delivery solutions using its NanoCluster formulation technology, which is now available for evaluation and license. Medicines manufactured using the NanoCluster technology are formulated directly from nanoparticle actives without the need for carrier particles or spray drying. The aerodynamics of NanoCluster formulations are fully customizable and permit targeted deposition of medicines to specific lung regions, including the deep lung. Savara expects that these NanoCluster features will translate into numerous patient benefits including reduced doses, enhanced efficacy, improved safety and tolerability as well as greater patient convenience.
Contact Information Media: Ian Stone Russo Partners, LLC (619) 528-2220 Ian.Stone@russopartnersllc.com Partners: Josef Bossart (512) 535-3613 Jbossart@savarapharma.com Investors: Rob Neville (512) 970-4740 Rob.Neville@savarapharma.comSOURCE Savara, Inc.
Source: PR Newswire
Related Articles
- Jobg8 Releases New Pay for Performance Product for Job Boards that are Network Members
- Hospital Association Names New Chairman, Appoints Board Officers and New Members
- Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act Increases to 27 Members
- Nanobac Pharmaceuticals, Inc. Announces Collaboration Agreement With BioChemics for Transdermal Therapeutic Formulation
- E-Future Appoints New Board and Audit Committee Member
- Hanford Boards Charter Revision Limits Member Terms
- Jobs Up for Grabs at 4 Schools: Under City Board's Restructuring Plans, Staff Members Must Reapply for Their Positions
- OAUG Elects New Board of Directors; New Members Further Enhance Organization's Ability to Represent Applications Community
- Keeneyville School Board Swears in Newest Member
- NanoOpto Announces Addition of Richard Hegberg to Board of Directors; Independent Member of Board Adds Broad Industry Expertise to Support Company Growth
 |
 |
User Comments (0)
RSS Feeds